Evidence map›Paper›PMID 30345204›Full record

ReviewCureus2018

An Overview of Light Chain Multiple Myeloma: Clinical Characteristics and Rarities, Management Strategies, and Disease Monitoring.

Abdul Rafae, Mustafa N Malik, Muhammad Abu Zar, Seren Durer, Ceren Durer

Registry-linked trialOpen access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cureus, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05439538 (Serum Neutrophil Gelatinase-associated Lipocalin), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05439538 unknown statusnot on this mapstarted 2022, after this paper: background citation

Serum Neutrophil Gelatinase-associated Lipocalin (NGAL) as a Predictor of Renal Injury in Patients With Multiple Myeloma

TypeobservationalSponsorAssiut UniversityRan2022 to 2025Enrolled60ConditionsMultiple Myeloma(MM)ArmsSERUM NGAL
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Light Chain Myeloma Precipitating Cryoglobulinemic Vasculitis.Journal of community hospital internal medicine perspectives · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Early Normalization of Free Light Chains Predicts Better Outcomes in Patients with Multiple Myeloma.International journal of hematology-oncology and stem cell research · 2020
    Article
  17. Skeletal Myopathy as the Initial Manifestation of Light Chain Multiple Myeloma.European journal of case reports in internal medicine · 2020
    Article
  18. Light-Chain Myeloma Presented as Osseus Tumors: A Case Report.Journal of investigative medicine high impact case reports
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Abdul RafaeHematology and Oncology, The University of Arizona, Tucson, USA.
Mustafa N MalikHematology and Oncology, The University of Arizona, Tucson, USA.
Muhammad Abu ZarHematology and Oncology, The University of Arizona, Tucson, USA.
Seren DurerHematology and Oncology, University of Arizona, Tucson, USA.
Ceren DurerHemtology and Oncology, The University of Arizona, Tucson, USA.
Arizona Oncology · USUniversity of Arizona · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Light chain multiple myeloma (LCMM) constitutes approximately 15% of patients with multiple myeloma (MM). It has a poorer prognosis when compared to immunoglobulin (Ig) G or IgA variant. We performed a comprehensive literature search on LCMM and identified a total of 390 articles. After a detailed screening, six studies involving a total of 1054 LCMM patients were included. A literature review revealed bone pain and renal failure as the most common initial sign and symptoms while extramedullary disease (EMD) was acquired later during the progression of the disease. Bortezomib has shown superior efficacy in LCMM patients over nonbortezomib regimens as demonstrated by better overall response rate (95.5% vs. 60%), progression-free survival (PFS) (25% vs. 9% at two years), and overall survival (OS) (24% vs. 9% at five years). Moreover, better PFS was seen, when bortezomib was used in combination with bendamustine compared to dexamethasone (95% vs. 25% at two years). Similarly, better OS (90% at two years) was observed with bortezomib in combination with bendamustine. Monitoring of disease should include serum free light chain levels, as literature review revealed that serum assays were more sensitive in indicating the disease and predicting PFS and OS as compared to urine assays. We provide presentation patterns, clinical rarities, management strategies including their efficacy, and disease monitoring in patients with LCMM in our review paper.

Indexed as

bortezomiblight chain only multiple myelomasurvival

Identifiers

PMID30345204
PMCPMC6191009
OpenAlexW2887808101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.